Comparison of outcomes of non–ENU-treated and ENU-treated mice
| . | T lymphoma or T-cell leukemia (%) . | Soft tissue sarcomas (%) . | MPD (%) . | Other (%) . | Alive (%)* . |
|---|---|---|---|---|---|
| WT | 0/18 (0) | 0/18 (0) | 0/18 (0) | 0/18 (0) | 18/18 (100) |
| Egr1+/− | 0/19 (0) | 0/19 (0) | 0/19 (0) | 0/19 (0) | 19/19 (100) |
| ENU-WT | 3/15 (20) | 1/15 (7) | 1/15 (7) | 0/15 (0) | 10/15 (67) |
| ENU-Egr1+/− | 2/15 (13) | 4/15 (27) | 8/15 (53) | 0/15 (0) | 1/15 (7) |
| Tp53+/− | 3/12 (25) | 4/12 (33) | 0/12 (0) | 0/12 (0) | 5/12 (42) |
| Egr1+/−, Tp53+/− | 0/14 (0) | 4/14 (29) | 0/14 (0) | 3/14 (21)† | 7/14 (50) |
| ENU-Tp53+/− | 10/16 (63) | 3/16 (19) | 1/16 (6) | 2/16 (12)‡ | 0/16 (0) |
| ENU-Egr1+/−, Tp53+/− | 13/18 (72) | 2/18 (11) | 1/18 (6) | 2/18 (11)§ | 0/18 (0) |
| . | T lymphoma or T-cell leukemia (%) . | Soft tissue sarcomas (%) . | MPD (%) . | Other (%) . | Alive (%)* . |
|---|---|---|---|---|---|
| WT | 0/18 (0) | 0/18 (0) | 0/18 (0) | 0/18 (0) | 18/18 (100) |
| Egr1+/− | 0/19 (0) | 0/19 (0) | 0/19 (0) | 0/19 (0) | 19/19 (100) |
| ENU-WT | 3/15 (20) | 1/15 (7) | 1/15 (7) | 0/15 (0) | 10/15 (67) |
| ENU-Egr1+/− | 2/15 (13) | 4/15 (27) | 8/15 (53) | 0/15 (0) | 1/15 (7) |
| Tp53+/− | 3/12 (25) | 4/12 (33) | 0/12 (0) | 0/12 (0) | 5/12 (42) |
| Egr1+/−, Tp53+/− | 0/14 (0) | 4/14 (29) | 0/14 (0) | 3/14 (21)† | 7/14 (50) |
| ENU-Tp53+/− | 10/16 (63) | 3/16 (19) | 1/16 (6) | 2/16 (12)‡ | 0/16 (0) |
| ENU-Egr1+/−, Tp53+/− | 13/18 (72) | 2/18 (11) | 1/18 (6) | 2/18 (11)§ | 0/18 (0) |
Mouse cohorts shown in Table 1 (and Figure 2) were bred on an Apcfl/+ (WT) background; the study was terminated at ∼500 days. The Apcfl/+(WT) mice, as with the Egr1+/+ (WT) mice, have been backcrossed to C57BL/6.
In comparison with the cohort presented in Figure 1, there were more Tp53+/− and Egr1+/−, Tp53+/− “alive” mice because the study was ended at an earlier time point. Consequently, no osteosarcomas or histiocytic sarcomas were observed because they occurred at later time points.
Two Egr1+/−, Tp53+/− mice were euthanized due to internal bleeding, and 1 died of unknown causes.
One ENU-Tp53+/− mouse was euthanized due to hind leg paralysis, and 1 developed a CD19+ IgM+ B-cell malignancy.
One ENU-Egr1+/−, Tp53+/−mouse was euthanized due to internal bleeding, and 1 developed splenomegaly with an increased proportion of CD71+ Ter119+ cells, but without anemia.